G L Kearns

Summary

Affiliation: Children's Mercy Hospital
Country: USA

Publications

  1. pmc Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics
    Robert M Ward
    Neonatology, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA
    Paediatr Drugs 15:119-31. 2013
  2. pmc Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics
    Craig A Friesen
    The Children s Mercy Hospital and Clinics, Kansas City, Missouri, USA
    BMC Gastroenterol 9:32. 2009
  3. ncbi request reprint Percutaneous lidocaine administration via a new iontophoresis system in children: tolerability and absence of systemic bioavailability
    Gregory L Kearns
    Departments of Pediatrics, University of Missouri Kansas City, Kansas City, USA
    Pediatrics 112:578-82. 2003
  4. ncbi request reprint Developmental pharmacology--drug disposition, action, and therapy in infants and children
    Gregory L Kearns
    Department of Pediatrics, University of Missouri at Kansas City, Kansas City, MO, USA
    N Engl J Med 349:1157-67. 2003
  5. ncbi request reprint Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny
    Gregory L Kearns
    Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Rd, Kansas City, MO 64108, USA
    Clin Pharmacol Ther 74:312-25. 2003
  6. ncbi request reprint Impact of ontogeny on linezolid disposition in neonates and infants
    Gregory L Kearns
    Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, MO 64108, USA
    Clin Pharmacol Ther 74:413-22. 2003
  7. ncbi request reprint Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics
    Gregory L Kearns
    University of Missouri Kansas City, and Chief, Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas, City Missouri, U S A
    J Pediatr Gastroenterol Nutr 37:S52-9. 2003
  8. ncbi request reprint Single dose pharmacokinetics of linezolid in infants and children
    G L Kearns
    Department of Pediatrics, University of Missouri Kansas City, USA
    Pediatr Infect Dis J 19:1178-84. 2000
  9. ncbi request reprint Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network
    G L Kearns
    Department of Pediatrics, University of Missouri Kansas City, MO, USA
    Pediatr Infect Dis J 19:833-9. 2000
  10. doi request reprint Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents
    Gregory L Kearns
    Division of Pediatric Pharmacology and Medical Toxicology, The Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    J Clin Pharmacol 48:1356-65. 2008

Research Grants

Collaborators

Detail Information

Publications62

  1. pmc Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics
    Robert M Ward
    Neonatology, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA
    Paediatr Drugs 15:119-31. 2013
    ..Prolonged treatment of pediatric patients with PPIs has not caused cancer or significant abnormalities...
  2. pmc Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics
    Craig A Friesen
    The Children s Mercy Hospital and Clinics, Kansas City, Missouri, USA
    BMC Gastroenterol 9:32. 2009
    ..The mechanism of this clinical response is unknown but could involve a decrease in eosinophil density or activation...
  3. ncbi request reprint Percutaneous lidocaine administration via a new iontophoresis system in children: tolerability and absence of systemic bioavailability
    Gregory L Kearns
    Departments of Pediatrics, University of Missouri Kansas City, Kansas City, USA
    Pediatrics 112:578-82. 2003
    ..For evaluating the tolerance of this IDDS in pediatrics, 12 healthy children (5-15 years, 4 girls and 8 boys, 10 white, weight 19-79 kg) were evaluated...
  4. ncbi request reprint Developmental pharmacology--drug disposition, action, and therapy in infants and children
    Gregory L Kearns
    Department of Pediatrics, University of Missouri at Kansas City, Kansas City, MO, USA
    N Engl J Med 349:1157-67. 2003
  5. ncbi request reprint Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny
    Gregory L Kearns
    Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Rd, Kansas City, MO 64108, USA
    Clin Pharmacol Ther 74:312-25. 2003
    ..This known developmental delay in the expression of CYP3A4 prompted us to conduct a classical open-label pharmacokinetic study of cisapride in neonates and young infants...
  6. ncbi request reprint Impact of ontogeny on linezolid disposition in neonates and infants
    Gregory L Kearns
    Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, MO 64108, USA
    Clin Pharmacol Ther 74:413-22. 2003
    ..Evaluation of the pharmacokinetic data would appear to support the use of linezolid dosing regimens currently approved for infants and young children in neonates with postnatal age greater than 7 days...
  7. ncbi request reprint Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics
    Gregory L Kearns
    University of Missouri Kansas City, and Chief, Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas, City Missouri, U S A
    J Pediatr Gastroenterol Nutr 37:S52-9. 2003
    ....
  8. ncbi request reprint Single dose pharmacokinetics of linezolid in infants and children
    G L Kearns
    Department of Pediatrics, University of Missouri Kansas City, USA
    Pediatr Infect Dis J 19:1178-84. 2000
    ..The safety and pharmacokinetics of intravenously administered linezolid were evaluated in children and adolescents to examine the potential for developmental dependence on its disposition characteristics...
  9. ncbi request reprint Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network
    G L Kearns
    Department of Pediatrics, University of Missouri Kansas City, MO, USA
    Pediatr Infect Dis J 19:833-9. 2000
    ..Pleconaril phamacokinetics was evaluated in 16 neonates (16.4 +/- 8.7 days postnatal age) with suspected enteroviral infection...
  10. doi request reprint Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents
    Gregory L Kearns
    Division of Pediatric Pharmacology and Medical Toxicology, The Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    J Clin Pharmacol 48:1356-65. 2008
    ..The pharmacokinetic profile of oral and intravenous pantoprazole was similar in children ages 2 to 16 years. The doses used here were safe and well tolerated in this population...
  11. doi request reprint Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis
    Gregory L Kearns
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    J Clin Pharmacol 48:502-11. 2008
    ....
  12. pmc Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Pediatric Pharmacology Research Unit Network
    G L Kearns
    Section of Pediatric Clinical Pharmacology and Experimental Therapeutics, Children s Mercy Hospital, Kansas City, Missouri, USA
    Antimicrob Agents Chemother 43:634-8. 1999
    ..e., 70 ng/ml). Thus, our data support the evaluation of a 5-mg/kg twice-daily oral dose of pleconaril for therapeutic trials in pediatric patients with enteroviral infections...
  13. ncbi request reprint Cefpodoxime pharmacokinetics in children: effect of food
    G L Kearns
    Section of Pediatric Clinical Pharmacology and Experimental Therapeutics, The Children s Mercy Hospital, Kansas City, MO 64108, USA
    Pediatr Infect Dis J 17:799-804. 1998
    ..We report the results of a randomized two-way crossover study designed to characterize the disposition of a single dose (10 mg/kg) of cefpodoxime proxetil oral suspension in children, under fed and fasted conditions...
  14. ncbi request reprint Evaluation of occult acetaminophen hepatotoxicity in hospitalized children receiving acetaminophen. Pediatric Pharmacology Research Unit Network
    L P James
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock 72202, USA
    Clin Pediatr (Phila) 40:243-8. 2001
    ..Acetaminophen-protein adducts were not detected in this cohort of 18 subjects. Based on this pilot study, the routine use of acetaminophen at therapeutic doses in ill, hospitalized children and adolescents appears safe...
  15. ncbi request reprint Investigation of terbinafine as a CYP2D6 inhibitor in vivo
    S M Abdel-Rahman
    Children s Mercy Hospital, and the Department of Pediatrics, Pharmacy Practice, Pharmacology, and the Pharmaceutical Sciences, University of Missouri Kansas City, 64108, USA
    Clin Pharmacol Ther 65:465-72. 1999
    ..This prospective open-label study was designed to confirm our previous finding that terbinafine may inhibit CYP2D6...
  16. ncbi request reprint Elevation of serum interleukin 8 levels in acetaminophen overdose in children and adolescents
    L P James
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children s Hospital, Little Rock 72202, USA
    Clin Pharmacol Ther 70:280-6. 2001
    ..The purpose of this study was to measure serum cytokine levels in children and adolescents with acetaminophen overdose and to evaluate relationships between cytokine elevation and hepatotoxicity...
  17. ncbi request reprint Ontogeny of dextromethorphan O- and N-demethylation in the first year of life
    M J Blake
    Division of Pediatric Pharmacology and Medical Toxicology, Department of Pediatrics, Children s Mercy Hospitals and Clinics, Kansas City, Missouri, USA
    Clin Pharmacol Ther 81:510-6. 2007
    ..In contrast, DM N-demethylation developed significantly more slowly over the first year of life. Genotype and the temporal acquisition of drug biotransformation are critical determinants of a drug response in infants...
  18. ncbi request reprint Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
    A Gaedigk
    Section of Pediatric Clinical Pharmacology and Experimental Therapeutics, The Children s Mercy Hospital, and University of Missouri Kansas City, 64108, USA
    Pharmacogenetics 9:669-82. 1999
    ..For all individuals, the correct phenotype has been predicted. Discordant phenotype assignment occurred in only two individuals which subsequently was attributed to CYP2D6 inhibition by concomitant drug therapy...
  19. ncbi request reprint Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms
    R E Pearce
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospital, Kansas City, Missouri 64108, USA
    Drug Metab Dispos 29:1548-54. 2001
    ..g., ontogeny of drug-metabolizing enzymes, inhibition, and induction) should be clinically unimportant due to the apparent lack of dependence on cytochromes P450 for elimination...
  20. doi request reprint Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target
    J S Leeder
    Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri, USA
    Clin Pharmacol Ther 92:434-6. 2012
    ....
  21. ncbi request reprint Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine
    S M Abdel-Rahman
    Section of Pediatric Clinical Pharmacology and Experimental Therapeutics, The Children s Mercy Hospital, Kansas City, Missouri 64108, USA
    Drug Metab Dispos 27:770-5. 1999
    ..This agent needs to be evaluated in vivo to determine the impact of CYP2D6 inhibition by terbinafine on the metabolism of concomitantly administered CYP2D6 substrates...
  22. ncbi request reprint Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo
    Jennifer A Lowry
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    Clin Pharmacol Ther 73:209-22. 2003
    ..Cisapride was compared with midazolam in vivo to determine its potential applicability as a cytochrome P450 (CYP) 3A4 "probe." As well, we evaluated whether cisapride was transported by P-glycoprotein...
  23. ncbi request reprint Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls
    S M Abdel-Rahman
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, The Children s Mercy Hospitals and Clinics, Kansas City, Missouri, USA
    Clin Pharmacol Ther 81:483-94. 2007
    ..Illustrations are provided from our experience, which highlight problems that may arise when trials are not designed with the pediatric patient in mind...
  24. ncbi request reprint Omeprazole disposition in children following single-dose administration
    Gregory L Kearns
    Departments of Pediatrics and Pharmacology, University of Missouri, Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, Missouri, USA
    J Clin Pharmacol 43:840-8. 2003
    ..No association between age and CL/F, t1/2, or lambda z was observed. The range of t1/2 values for omeprazole was similar to those reported in adults (1-1.5 h)...
  25. ncbi request reprint Developmental pharmacokinetics and pharmacodynamics of nizatidine
    Susan M Abdel-Rahman
    Children s Mercy Hospital, Kansas City, Missouri, 64108, USA
    J Pediatr Gastroenterol Nutr 38:442-51. 2004
    ..To characterize the impact of development on the pharmacokinetics and pharmacodynamics of nizatidine...
  26. doi request reprint Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics
    Jason G Newland
    Department of Pediatrics, University of Missouri Kansas City, Kansas City, Missouri, USA
    Paediatr Drugs 10:367-78. 2008
    ..In other invasive MRSA infections, such as pneumonia and musculoskeletal infections, the empiric treatment of choice is clindamycin. Finally, newer agents and additional treatment options are discussed...
  27. doi request reprint Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections
    Susan M Abdel-Rahman
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, The Children s Mercy Hospital, University of Missouri, Kansas City, MO 64108, USA
    Pediatr Infect Dis J 27:330-4. 2008
    ..Although the pharmacokinetics of daptomycin have been well characterized in adults, no studies have evaluated the pharmacokinetics and tolerability in a pediatric population...
  28. doi request reprint Single-dose pharmacokinetics of roflumilast in children and adolescents
    Kathleen A Neville
    Department of Pediatrics, University of Missouri Kansas City and the Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64079, USA
    J Clin Pharmacol 48:978-85. 2008
    ..1 and 0.8 microg/L per 1 microg/kg dose for adolescents and children, respectively), pharmacokinetic parameters for roflumilast and roflumilast N-oxide were not different between age groups and were similar to adults...
  29. doi request reprint Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science
    J Steven Leeder
    Division of Clinical Pharmacology and Medical Toxicology, Department of Pediatrics, Children s Mercy Hospitals and Clinics, School of Medicine, University of Missouri Kansas City, 2401 Gillham Road, Kansas City, MO 64108, USA
    J Clin Pharmacol 50:1377-87. 2010
    ..The results of the analysis can be used to aid in the design of studies to yield maximally informative data in pediatric populations of different ages and developmental stages and thereby improve the efficiency of study design...
  30. ncbi request reprint Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants
    Michael J Blake
    Department of Pediatrics, University of Missouri Kansas City, School of Medicine and the Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, Missouri 64108, USA
    Pediatr Res 60:717-23. 2006
    ..Dietary modification of CYP activity may modulate drug biotransformation and thus alter systemic exposure to xenobiotics from a very early age...
  31. ncbi request reprint Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia
    Craig A Friesen
    Section of Gastroenterology, The Children s Mercy Hospital and Clinics, Kansas City, Missouri 64108, USA
    J Pediatr Gastroenterol Nutr 38:343-51. 2004
    ..We evaluated the effect of this drug in children with eosinophilic duodenitis, defined histologically as duodenal mucosa with peak eosinophil count of more than 10 eosinophils/hpf...
  32. doi request reprint Developmental pharmacogenomics
    Kathleen A Neville
    Department of Pediatrics, University of Missouri Kansas City, Kansas City, MO, USA
    Paediatr Anaesth 21:255-65. 2011
    ....
  33. doi request reprint Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant
    Susan M Abdel-Rahman
    Division of Clinical Pharmacology and Medical Toxicology, The Childrens Mercy Hospitals and Clinics, Kansas City, Missouri 64108, USA
    Paediatr Drugs 13:19-31. 2011
    ..In addition, the available pediatric pharmacokinetic data for oseltamivir and its active metabolite are summarized and current 'information gaps' deserving of future study are presented...
  34. ncbi request reprint Characterization of delayed liquid gastric emptying in children by the (13)C-acetate breath test
    B L Jones
    Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, MO, USA Department of Pediatrics, University of Missouri Kansas City, 2401 Gillham Rd Kansas City, MO, USA
    J Breath Res 3:047004. 2009
    ....
  35. ncbi request reprint GC-MS determination of amphetamine and methamphetamine in human urine for 12 hours following oral administration of dextro-methamphetamine: lack of evidence supporting the established forensic guidelines for methamphetamine confirmation
    J L Valentine
    Department of Pediatrics, University of Arkansas for Medical Sciences and Toxicology, Arkansas Children s Hospital, Little Rock 72202 3591, USA
    J Anal Toxicol 19:581-90. 1995
    ....
  36. ncbi request reprint Rifapentine pharmacokinetics in adolescents
    J D Marshall
    Department of Pediatrics, University of Missouri Kansas City, USA
    Pediatr Infect Dis J 18:882-8. 1999
    ..Determination of rifapentine pharmacokinetics in healthy adolescent children...
  37. ncbi request reprint The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule
    Susan M Abdel-Rahman
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospital and Clinics, 2401 Gillham Road, Suite 0411, Kansas City, MO 64108, USA
    J Clin Pharmacol 43:148-53. 2003
    ..g., 0.80-1.25). Thus, nizatidine in infant formula and the commercially prepared oral syrup can be considered bioequivalent to the reference capsule...
  38. doi request reprint Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement
    Mary Jayne Kennedy
    Kosair Charities Pediatric Clinical Research Unit, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, Kentucky 40202, USA
    Clin Ther 30:1687-99. 2008
    ..Although growth hormone (GH) may alter the clearance of concomitantly administered medications, its effects on individual drug-metabolizing enzymes in children have not been characterized...
  39. ncbi request reprint Single-dose pharmacokinetics of nizatidine (Axid) in children
    Susan M Abdel-Rahman
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospital and Clinics, Kansas City, Missouri 64108, USA
    J Clin Pharmacol 42:1089-96. 2002
    ..Finally, nizatidine plasma concentrations in pediatric patients following a single 5.0 mg/kg oral dose exceeded the EC50 value of the drug for gastric acid suppression determined from adult studies for approximately 6 hours...
  40. ncbi request reprint Developmental pharmacodynamics of cyclosporine
    J D Marshall
    Department of Pediatrics, University of Missouri Kansas City, Children s Mercy Hospital, 64108, USA
    Clin Pharmacol Ther 66:66-75. 1999
    ..To determine the relationship between human development and in vitro cyclosporine (INN, ciclosporin) pharmacodynamics...
  41. ncbi request reprint The challenges of delivering pharmacogenomics into clinical pediatrics
    J S Leeder
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospital and Clinics, Kansas City, MO 64108, USA
    Pharmacogenomics J 2:141-3. 2002
  42. ncbi request reprint Pediatric acetaminophen overdose: risk factors associated with hepatocellular injury
    S W Alander
    Department of Pediatrics, Children s Mercy Hospital, Kansas City, MO 64108, USA
    Arch Pediatr Adolesc Med 154:346-50. 2000
    ..To characterize demographic and clinical factors associated with pediatric acetaminophen overdose and identify risk factors for hepatocellular injury...
  43. pmc Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect
    Gregory L Kearns
    Director, Pharmacogenetics Core Laboratory, Division of Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    Drug Metab Dispos 38:894-7. 2010
    ..0001) and the apparent elimination rate constant (K(el); p = 0.0012); no significant genotype-phenotype relationships were observed for omeprazole...
  44. ncbi request reprint Pharmacokinetics of rifapentine in children
    Michael J Blake
    Department of Pediatrics, University of Missouri Kansas City, School of Medicine, USA
    Pediatr Infect Dis J 25:405-9. 2006
    ..Although the pharmacokinetics of rifapentine has been investigated in adolescents and adults, no studies have assessed the pharmacokinetics of this drug in children or infants...
  45. ncbi request reprint Biotransformation of fluticasone: in vitro characterization
    Robin E Pearce
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Department of Pediatrics, Children s Mercy Hospitals and Clinics, Kansas City, MO 64108, USA
    Drug Metab Dispos 34:1035-40. 2006
    ..These results suggest that at pharmacologically relevant concentrations, biotransformation of FTP to M1 is mediated predominantly by CYP3A enzymes in the liver...
  46. ncbi request reprint Ontogeny of drug metabolizing enzymes in the neonate
    Michael J Blake
    Department of Pediatrics, University of Missouri Kansas City, Division of Pediatric Pharmacology and Medical Toxicology, The Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    Semin Fetal Neonatal Med 10:123-38. 2005
    ....
  47. ncbi request reprint Coadministration of mefloquine and chloroqine: use of a pharmacokinetic-based approach to reduce toxicity
    J A Lowry
    Division of Clinical Pharmacology and Toxicology, Children's Mercy Hospital and Clinics, Kansas City, MO 64108, USA
    Pediatr Infect Dis J 20:223-4. 2001
    ..A child with malaria from a chloroquine-resistant area received an accidental overdose of chloroquine administered by a parent. Application of pharmacokinetics permitted definitive treatment with mefloquine in a safe and effective manner...
  48. ncbi request reprint Measurement of acetaminophen-protein adducts in children and adolescents with acetaminophen overdoses.
    L P James
    Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock 72202, USA
    J Clin Pharmacol 41:846-51. 2001
    ....
  49. ncbi request reprint Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation
    S M Abdel-Rahman
    Department of Pediatrics, University of Missouri Kansas City, USA
    J Clin Pharmacol 42:24-9. 2002
    ....
  50. ncbi request reprint Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis
    Mary Jayne Kennedy
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, The Children s Mercy Hospitals and Clinics, Kansas City, MO, USA
    Clin Pharmacol Ther 75:163-71. 2004
    ..Altered biotransformation of drugs in this patient population is likely enzyme- and isoform-specific and thus is apparent for only selected compounds that are substrates for enzymes other than CYP1A2, NAT-2, XO, and CYP2D6...
  51. ncbi request reprint Cytokines and toxicity in acetaminophen overdose
    Laura P James
    Department of Pediatrics, Section of Clinical Pharmacology and Toxicology, Arkansas Children s Hospital, 800 Marshall Street, Little Rock, AR 72202, USA
    J Clin Pharmacol 45:1165-71. 2005
    ..An understanding of the role of cytokine responses in acetaminophen overdose may be relevant to the future development of new therapies for acetaminophen toxicity...
  52. ncbi request reprint Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old
    Elizabeth Migoya
    Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, NJ 07065, USA
    J Clin Pharmacol 44:487-94. 2004
    ..Observed plasma concentrations were also similar. Based on systemic exposure of montelukast, a 4-mg dose of montelukast appears appropriate for children as young as 6 months of age...
  53. ncbi request reprint Levofloxacin pharmacokinetics in children
    Shuchean Chien
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 920 Route 202 South, PO Box 300, Raritan, NJ 08869 0602, USA
    J Clin Pharmacol 45:153-60. 2005
    ....
  54. ncbi request reprint Pharmacokinetics of intravenously administered azithromycin in pediatric patients
    Richard F Jacobs
    Division of Pediatric Infectious Disease, Arkansas Children s Hospital, 800 Marshall Street, Little Rock, AR 72202, USA
    Pediatr Infect Dis J 24:34-9. 2005
    ..The objective of this study was to characterize the pharmacokinetics and tolerance of a single intravenous (IV) azithromycin dose in children...
  55. ncbi request reprint Pharmacokinetics of famotidine in infants
    Larissa A Wenning
    Merck Research Laboratories, West Point, Pennslyvania, USA
    Clin Pharmacokinet 44:395-406. 2005
    ..Little is currently known about the pharmacokinetics of famotidine in infants aged between 1 month and 1 year, a period when renal function is maturing...
  56. ncbi request reprint Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail"
    Siwaporn Chainuvati
    Department of Medicine, Bassett Healthcare, Cooperstown, NY 13326, USA
    Clin Pharmacol Ther 74:437-47. 2003
    ..The Cooperstown 5+1 cocktail may be used to simultaneously assess the activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT2, and XO...
  57. ncbi request reprint The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants
    Gloria P Heresi
    Division of Pediatrics Infectious Diseases, UT Medical School at Houston, Houston, TX, USA
    Pediatr Infect Dis J 25:1110-5. 2006
    ..The objective of this study was to determine the safety and pharmacokinetics of micafungin in premature infants...
  58. ncbi request reprint Genetics of warfarin response
    Kathleen A Neville
    N Engl J Med 358:2742. 2008
  59. ncbi request reprint Famotidine disposition in children and adolescents with chronic renal insufficiency
    Holly D Maples
    University of Arkansas for Medical Sciences, Arkansas Children s Hospital, Little Rock, Arkansas, USA
    J Clin Pharmacol 43:7-14. 2003
    ..6% Clnr) (p < 0.05). It was concluded that the pharmacokinetics of famotidine are significantly altered in children with chronic renal insufficiency; accordingly, dosing should be based on glomerular filtration rate (i.e., Clcr)...
  60. pmc Population pharmacokinetic model for gatifloxacin in pediatric patients
    Christopher M Rubino
    Cognigen Corporation, Buffalo, NY, USA
    Antimicrob Agents Chemother 51:1246-52. 2007
    ..The success of this strategy provides a model for future pediatric drug development programs...
  61. pmc Pharmacokinetics of gatifloxacin in infants and children
    Edmund V Capparelli
    Pediatric Pharmacology Research Unit, University of California, San Diego, California, USA
    Antimicrob Agents Chemother 49:1106-12. 2005
    ..h/ml (estimated free AUC/MIC ratio of > or =34 for MIC of < or =0.5 microg/ml). These data suggest that gatifloxacin at a dose of 10 mg/kg every 24 h will achieve therapeutic concentrations in plasma in infants and children...
  62. ncbi request reprint Divalproex-ER pharmacokinetics in older children and adolescents
    Sandeep Dutta
    Abbott Laboratories, Abbott Park, Illinois, USA
    Pediatr Neurol 30:330-7. 2004
    ....

Research Grants4

  1. CHILDREN'S CENTER FOR CLINICAL PHARMACOLOGY STUDIES
    Gregory Kearns; Fiscal Year: 2007
    ..abstract_text> ..